BTCY · Biotricity Inc.
Substantial doubt about the company's ability to continue as a going concern.
“Management has previously noted the existence of substantial doubt about our ability to continue as a going concern. Additionally, our independent registered public accounting firm included an explanatory paragraph in the report on our financial statements as of and for the years ended March 31, 2026 and 2025, respectively, noting the existence of substantial doubt about our ability to continue as a going concern.”View the 10-K filed Jul 14, 2026
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | $16M | $13.79M | $12.06M | $9.64M | $7.65M | $3.38M | $1.42M | $398.2K | — | — | — | — | |
| — | $3.05M | $3.23M | $3.71M | $4.2M | $3.08M | $2.11M | $931.95K | $338.34K | — | — | — | — | |
| — | $12.95M | $10.56M | $8.36M | $5.44M | $4.57M | $1.27M | $485.77K | $59.87K | — | — | — | — | |
| — | 80.94% | 76.61% | 69.27% | 56.46% | 59.74% | 37.6% | 34.26% | 15.03% | — | — | — | — | |
| — | $2.76M | $2.16M | $2.57M | $3.23M | $2.74M | $2.06M | $1.36M | $1.31M | $1.76M | $1.14M | $1.09M | $1.14M | |
| $20.47M | — | — | — | — | $19.85M | $12.57M | $10.05M | $7.34M | $5.96M | $4.8M | $3.88M | $3.99M | |
| — | $8.49M | $10.86M | $14.61M | $17.62M | $18.56M | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | $1000 | |
| — | — | — | — | — | — | $2.48M | $92.42K | — | — | — | — | $0 | |
| — | $11.26M | $13.01M | $17.18M | $20.85M | $21.31M | $14.62M | $11.42M | $8.65M | $7.72M | $5.94M | $4.97M | $5.13M | |
| — | $1.69M | -$2.45M | -$8.83M | -$15.41M | -$16.74M | — | — | — | — | — | — | — | |
| — | 10.57% | -17.76% | -73.18% | -159.87% | -218.77% | — | — | — | — | — | — | — | |
| — | $3.36M | $3.26M | $3.02M | $1.84M | $1.28M | — | — | — | — | — | — | — | |
| — | $159.98K | -$78.57K | -$102.61K | -$110.82K | $15.12K | $36.64K | -$16.94K | — | — | — | — | — | |
| — | -$2.4M | -$8.42M | -$14.09M | -$18.66M | -$29.13M | -$15.49M | -$11.07M | -$8.59M | -$8.62M | — | — | — | |
| — | -$2.4M | -$8.42M | -$14.09M | -$18.66M | -$29.13M | -$15.49M | -$11.07M | -$8.59M | -$8.62M | -$7.81M | -$7.28M | -$5.19M | |
| — | -15.03% | -61.07% | -116.84% | -193.57% | -380.78% | -457.67% | -780.61% | -2157.73% | — | — | — | — | |
| — | -$3.13M | -$11.94M | -$14.93M | -$19.53M | -$30.22M | -$16.45M | -$11.32M | -$8.59M | — | — | — | — | |
| — | -$3.16M | -$11.83M | -$14.74M | -$18.92M | -$30.35M | -$16.23M | -$11.43M | -$8.7M | -$8.85M | — | — | -$5.22M | |
| USD/shares | — | -$0.12 | -$0.56 | -$1.66 | -$2.26 | -$3.99 | -$2.63 | — | — | — | — | — | — |
| USD/shares | — | -$0.12 | -$0.56 | -$1.66 | -$2.26 | — | — | — | — | — | — | — | — |
| shares | — | 27.3M | 21.52M | 8.99M | 8.66M | 7.57M | 6.25M | 5.99M | 5.56M | 5.03M | 4.31M | 4.3M | 2.69M |
| shares | — | 27.3M | 21.52M | 8.99M | 8.66M | — | 6.25M | 5.99M | 5.56M | 5.03M | 4.31M | 4.3M | 2.69M |
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2020–FY2021: $782.97K in dividends.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 38 similar-size Medical Devices companies (of 148 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Technology Fees | $14,440,900 | $12,591,036 | $11,249,113 | $8,802,032 | $5,904,393 | $2,748,866 |
| Device Sales | $1,557,339 | $1,199,258 | $814,232 | $837,025 | $995,876 | $635,901 |
| Service Related and Other Revenue | — | — | — | — | $750,000 | — |